

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Figure 1/12









Figure 2/12




Figure 3/12






Figure 4/12



## Figure 5/12

### Seq ID NO: 1

human Survivin

Genbank accession no. NM\_001168

```
1   CCGCCAGATT TGAATCGCGG GACCCGTTGG CAGAGGTGGC GGCGGCGGCA
51  TGGGTGCCCC GACGTTGCCC CCTGCCTGGC AGCCCTTCT CAAGGACCAC
101 CGCATCTCTA CATTCAAGAA CTGGCCCTTC TTGGAGGGCT GCGCCTGCAC
151 CCCGGAGCGG ATGGCCGAGG CTGGCTTCAT CCACTGCCCC ACTGAGAACG
201 AGCCAGACTT GGCCCAAGTGT TTCTTCTGCT TCAAGGAGCT GGAAGGCTGG
251 GAGCCAGATG ACGACCCCAT AGAGGAACAT AAAAAGCATT CGTCCGTTG
301 CGCTTTCCTT TCTGTCAAGA AGCAGTTTGA AGAATTAACC CTTGGTGAAT
351 TTTTGAAGCT GGACAGAGAA AGAGCCAAGA ACAAATATGC AAAGGAAACC
401 AACATAAGA AGAAAGAATT TGAGGAAACT GCGAAGAAAG TCGCGCGTGC
451 CATCGAGCAG CTGGCTGCCA TGGATTGAGG CCTCTGGCCG GAGCTGCCTG
501 GTCCAGAGT GGCTGCACCA CTTCCAGGGT TTATCCCTG GTGCCACCAG
551 CCTTCCTGTG GGCCCTTAG CAATGTCTTA GGAAAGGAGA TCAACATTTT
601 CAAATTAGAT GTTTCAACTG TGCTCCTGTT TTGTCTTGAA AGTGGCACC
651 GAGGTGCTTC TGCCTGTGCA GCGGGTGCTG CTGGTAACAG TGGCTGCTTC
701 TCTCTCTCTC TCTCTTTTTT GGGGGCTCAT TTTTGCTGTT TTGATTCCCG
751 GGCTTACCAG GTGAGAAGTG AGGGAGGAAG AAGGCAGTGT CCCTTTTGCT
801 AGAGCTGACA GCTTTGTTCG CGTGGGCAGA GCCTTCCACA GTGAATGTGT
851 CTGGACCTCA TGTGTTGAG GCTGTCACAG TCCTGAGTGT GGACTTGGCA
901 GGTGCCTGTT GAATCTGAGC TGCAGGTTC TTATCTGTCA CACCTGTGCC
951 TCCTCAGAGG ACAGTTTTTT TGTTGTTGTG TTTTTTGT TTTTTTTTTT
1001 GGTAGATGCA TGACTTGTGT GTGATGAGAG AATGGAGACA GAGTCCCTGG
1051 CTCCTCTACT GTTTAACAAC ATGGCTTTCT TATTTGTTT GAATTGTTAA
1101 TTCACAGAAT AGCACAAACT ACAATTAAAA CTAAGCACAA AGCCATTCTA
1151 AGTCATTGGG GAAACGGGGT GAACTTCAGG TGGATGAGGA GACAGAATAG
1201 AGTGATAGGA AGCGTCTGGC AGATACTCCT TTTGCCACTG CTGTGTGATT
1251 AGACAGGCCC AGTGAGCCGC GGGGCACATG CTGGCCGCTC CTCCTCAGA
1301 AAAAGGCAGT GGCCTAAATC CTTTTTAAAT GACTTGGCTC GATGCTGTGG
1351 GGGACTGGCT GGGCTGCTGC AGGCCGTGTG TCTGTCAGCC CAACCTTCAC
1401 ATCTGTCACG TTCTCCACAC GGGGGAGAGA CGCAGTCCGC CCAGGTCCCC
1451 GCTTCTTTG GAGGCAGCAG CTCCCGCAGG GCTGAAGTCT GGCGTAAGAT
1501 GATGGATTG ATTGCCCCC CTCCCTGTCA TAGAGCTGCA GGGTGGATTG
1551 TTACAGCTTC GCTGGAAACC TCTGGAGGTC ATCTCGGCTG TTCCTGAGAA
1601 ATAAAAAGCC TGTCATTTC
```

Figure 6/12




Figure 7/12









Figure 8/12  
Caspase3/7 measurement 24h following oligo treatment



# Figure 9/12

## Caspase 3 CBA assay 15PC3



## PARP CBA assay 15PC3





Figure 10/12



# Figure 11/12

Proliferation of 15PC3 treated with survivin antisense oligonucleotides 44 hours post transfection




Figure 12/12

